meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
atezolizumab plus cabozantinib
camrelizumab based treatment
durvalumab based treatment
durvalumab plus bevacizumab
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab plus lenvatinib
sintilimab based treatment
sintilimab
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab
versus all
vs non active control
vs placebo
vs VEGF(R) inhibitor
vs lenvatinib
vs sorafenib
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
deaths (OS)
mHCC - 1st line (L1)
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - 1st line (L1)
versus sorafenib
sintilimab vs. sorafenib
1
certainty unassessable
statistically conclusive
-40%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open